

(19)



Europäisches Patentamt
European Patent Office
Office européen des brevets

(11)

Publication number:

0 240 352
A2

(12)

EUROPEAN PATENT APPLICATION

(21) Application number: 87302884.9

(22) Date of filing: 02.04.87

(51) Int. Cl.⁴: **C 07 D 239/54**
C 07 D 401/12,
C 07 D 403/12, A 61 K 31/505

(30) Priority: 02.04.86 JP 74297/86
03.02.87 JP 21727/87

(43) Date of publication of application:
07.10.87 Bulletin 87/41

(84) Designated Contracting States: DE FR GB

(71) Applicant: Chisso Corporation
6-32, Nakanoshima 3-chome Kita-ku
Osaka-shi Osaka-fu (JP)

(72) Inventor: Yoshizawa, Ryo
1-5-404, Grin Haitzu 363 Nagasawa
Yokosuka-shi Kanagawa-ken (JP)


Kawashima, Masatoshi
10-3, Otsutomo-cho Kanazawa-ku
Yokohama-shi Kanagawa-ken (JP)

Yano, Hitoshi
12-16, Kannon-cho 1-chome Kawasaki-ku
Kawasaki-shi Kanagawa-ken (JP)

(74) Representative: Whalley, Kevin et al
MARKS & CLERK 57/60 Lincoln's Inn Fields
London WC2A 3LS (GB)

(54) 5-Fluorouracil derivatives and processes for producing thereof.

(57) 5-Fluorouracil derivatives of this invention are represented by a general formula:



(I)



wherein R indicates a non-substituted or substituted alkylene group having 0-10 carbon atoms, A indicates an atomic group of -NH- and -CO-, n is 0 or 1, and Y indicates a non-substituted or substituted alkyl group having 1-10 carbon atoms, a non-substituted or substituted aryl group, a non-substituted or substituted heteroaryl group, a pyridinium ion having a halogen as a pair ion or an isocyanate group.

These derivatives are useful as anticancer medicines and intermediates thereof and have lower toxicity than usual compounds.

These derivatives are produced by specified six methods of this invention. Representative method is a process which comprises reacting 5-fluorouracil and an isocyanate represented by a general formula:

Y - (A)_n - R - NCO (VII)

wherein R, A, n and Y are the same as those indicated in the formula (I).

EP 0 240 352 A2

Description

5-FLUOROURACIL DERIVATIVES AND PROCESSES FOR PRODUCING THEREOF


This invention relates to new 5-fluorouracil derivatives useful for an anticancer medicine or intermediates thereof and processes for producing thereof.

Hitherto, 5-fluorouracil and its derivatives such as 1-(2-tetrahydrofuranyl)-5-fluorouracil, 1-hexylcarbamoyl-5-fluorouracil, etc. has been known as anticancer medicines.

However, as these compounds have toxicity, they exert a bad influence upon a living body. In cases of doses for oral administration, there are disadvantages of digestive troubles. For this reason, when these compounds are dosed as an anticancer medicine, it needs to lower its toxicity. In case of being lower toxicity, the anticancer effect is lower, so that there is a problem that the anticancer medicine must be dosed in large quantities. Further, it is difficult to refine a desired product and to get a purified compound.

The purpose of this invention is to offer an anticancer medicine which has the anticancer effect and lower toxicity as a purified product.

Namely, this invention provides 5-fluorouracil derivatives represented by a general formula:




wherein R indicates a non-substituted or substituted alkylene group having 0-10 carbon atoms, A indicates an atomic group of -NH- and -CO-, n is 0 or 1, and Y indicates a non-substituted or substituted alkyl group having 1-10 carbon atoms, a non-substituted or substituted aryl group, a non-substituted or substituted heteroaryl group, a pyridinium ion having a halogen as a pair ion or an isocyanate group.

The compounds of this invention are new and useful for an anticancer medicine or an intermediate thereof which has the antitumor effect.


This invention also provides processes for producing 5-fluorouracil derivatives represented by the general formula(I).

The compounds of this invention are produced by the following processes.

The first method is a process obtained by reacting 5-fluorouracil and an isocyanate represented by a general formula:



wherein R, A, n and Y are the same groups and numbers as those indicated in the formula (I). This reaction is illustrated in the following equation.



As the isocyanate (VII) which is used in this process, 2-thienyl isocyanate, 2-thiazolyl isocyanate,

2-chloroethyl isocyanate, 3-chloropropyl isocyanate, 5-bromopentyl isocyanate, 1-oxopyridine-3 isocyanate, 3-indolylmethyl isocyanate, benzamidomethyl isocyanate, nicotinamidomethyl isocyanate, ethylene diisocyanate, 1,3-trimethylene diisocyanate, 1,6-hexamethylene diisocyanate, 1,10-decamethylene diisocyanate, 2-isocyanatoethylpyridinium chloride, 5-isocyanatoheptyl pyridinium bromide, 7-isocyanatoheptylpyridinium iodide, 2- (3-phenylureido)ethyl isocyanate, 3- [3- (pyridine-3-yl)ureido] propyl isocyanate, 6- [3- (pyridine-3-yl)ureido] hexyl isocyanate, 6- [3- (4 -sulfamoylphenyl)ureido] hexyl isocyanate, 6- (3-nicotinamidoureido) hexyl isocyanate, 6- (3-hexylureido)hexyl isocyanate, 6- [3- (3-dimethylaminopropyl)ureido] hexyl isocyanate, etc. can be exemplified.

These isocyanates can be commercially obtained or produced by suitable processes to be used appropriately.

As a suitable process, a process for producing from amine and dichlorocarbonyl, a process for producing from corresponding carboxylic acid azide by Curtius method, a process for producing from corresponding amine and trichloromethylchloro formate, a process for producing from corresponding olefin and isocyanic acid, etc. can be exemplified.

The ratio of 5-fluorouracil to the isocyanate preferably varies from 1.5:1 to 1:1.5 by mole.

As reaction solvent, benzene, toluene, tetrahydrofuran, dioxane, acetonitrile, dimethyl formamide, dimethyl sulfoxide, ethyl acetate, chloroform, pyridine, triethylamine, etc. can be exemplified.



The range of reaction temperature is 40-100 °C. To obtain the conclusion of the reaction, the final temperature is preferably above 80°C.

Reaction time varies depending on the reactivity of isocyanate. The range is suitably from 0.5 to 24 hours.

The second method is a process obtained by reacting 5-fluorouracil and a carboxylic acid azide represented by the corresponding formula:

Y- (A)_n - R - CON₃ (VIII)

wherein R, A, n and Y are the same as those indicated in the formula (I). This reaction is illustrated in the following equation.



As the carboxylic acid azide (VIII) which is used in this process, 2-thenoyl azide, 2-thiazolylcarbonyl azide, 3-chloropropionyl azide, 6-bromohexanoyl azide, 4-chlorobutyryl azide, 1-oxopyridine-3-carbonyl azide, indol-3-carbonyl azide, indol-3-acetyl azide, benzamidoacetyl azide, succinyl diazide, glutaryl diazide, octanedioyl diazide, dodecandioyl diazide, pyridinium-1-propionyl azide chloride, pyridinium-1-hexanoyl azide bromide, pyridinium-1-octanoyl azide iodide, 3-(3-phenylureidopropionyl azide, 4- [3- (pyridine-3-yl)ureido] butyryl azide, 7- [3- (pyridine-2-yl)ureido] heptanoyl azide, 7- [3- (4-sulfamoylphenyl)ureido] heptanoyl azide, 7- (3-nicotinamidoureido) heptanoyl azide, 7- [3- (3-hexylureido) heptanoyl azide, 7- [3- (3-dimethylaminopropyl)ureido] heptanoyl azide, etc. can be exemplified.

These carboxylic acid azides generally can be produced by the usual technique from a corresponding carboxylic acid, acid hydrazide, etc..

The ratio of 5-fluorouracil to the carboxylic acid azide preferably varies from 1.5:1 to 1:1.5 by mole.


As reaction solvent, benzene, toluene, tetrahydrofuran, dioxane, acetonitrile, dimethyl formamide, dimethyl sulfoxide, ethyl acetate, chloroform, pyridine, triethylamine, etc. can be exemplified.

The range of reaction temperature is 40-100 °C. To obtain the conclusion of the reaction, the final temperature is preferably above 80°C.

Reaction time varies depending on the reactivity of carboxylic acid azide. The range is suitably from 0.5 to 24


hours.

The third method is a process for reacting a 5-fluorouracil derivative containing an isocyanate group represented by the general formula (IV):




15 wherein R has the same meaning as in the general formula (I), and a compound represented by the formula: $H - Z - Y$ (X)

wherein Y has the same meaning as in the general formula (I), and Z indicates $-NH-$ or $-NHNH-CO-$ group, to obtain a 5-fluorouracil derivative represented by the general formula:



30 wherein R, Z and Y are the same as those indicated in the above formula.

This reaction is illustrated in the following equation.



55 The 5-fluorouracil derivative (IV) having the isocyanate group, when Y of the isocyanate $Y-(A)_n-R-NCO$ (VII) is isocyanate group $(-NCO)$ and $n=0$, can be readily obtained. The compound (IV) is preferably used after isolation and purification of reaction mixture. However, it can be used as a crude compound or a reaction mixture.

60 The compound represented by the general formula (X) which is used in this reaction can be readily obtained. As the compound, hexylamine, N,N-dimethyl 1,3-propanediamine, phenethylamine, aniline, 2-aminopyridine, 3-aminopyridine, 2-aminothiazole, 2-aminodiazole, 4-aminobenzenesulfonamide, benzoylhydrazide, picolinoylhydrazide, nicotinoylhydrazide, etc. can be exemplified.


65 The ratio of the compound represented by the general formula (IV) to the compound represented by the general formula (X) is preferably 1.5:1 to 1:1.5 by mole. As reaction solvent, benzene, toluene, tetrahydrofuran,

dioxane, acetonitrile, dimethyl formamide, dimethyl sulfoxide, ethyl acetate, chloroform, pyridine, triethylamine, etc. can be exemplified.

The range of reaction temperature is 40-100 °C.



Reaction time varies depending on the reactivity of the compound (IV) and the compound (X). The range is suitably from 0.5 to 24 hours.

The fourth method is a process for reacting a 5-fluorouracil derivative represented by the general formula:



wherein R has the same meaning as in the formula (I) and X indicates a halogen consisting of Cl, Br or I, and pyridine to obtain a 5-fluorouracil derivative represented by the general formula (III).

This reaction is illustrated in the following equation.



The 5-fluorouracil derivative (X II) used in this reaction, when Y of the isocyanate Y-(A)_n-R-NCO (VII) is a halogen (Cl, Br or I) and n=0, can be readily obtained by the reaction of the isocyanate (VII) with 5-fluorouracil.

The compound (X II) is preferably used after isolation and purification of the reaction product. However, it can be used as a crude compound or a reaction mixture.


The ratio of pyridine to the compound represented by the general formula (X II) is preferably above 1 by mole. Pyridine can be used as reaction solvent.

The range of reaction temperature is 30-100 °C.

Reaction time varies depending on the reactivity of the compound (X II). The range is suitably from 0.5 to 24 hours.

The fifth method for obtaining the compound of this invention is described.

In this method, the pyridinium compound (III) is produced by one step from three components of 5-fluorouracil, halogenoisocyanate: X-R-NCO (X III) wherein R has the same meaning as in the general formula (I), and X is a halogen which is Cl, Br or I, and pyridine. This reaction is illustrated in the following equation.




The ratio of 5-fluorouracil to the compound represented by the general formula (X III) is preferably 1.5:1 to 1:1.5 by mole.

Above 1 by mole ratio of pyridine to the component having greater moles in said two components is preferable. As reaction solvent, pyridine is preferably used in excess.

The range of reaction temperature is 40-100 °C.

Reaction time is suitably from 0.5 to 24 hours. In case of less than 0.5 hours, the reaction to obtain the pyridinium is incomplete because the reaction rate is small, and it is difficult to obtain the pure objective.

The sixth method is a process for reacting 1-chlorocarbonyl-5-fluorouracil (X IV) and a corresponding amine (X V) in a solvent as illustrated in the following equation,



wherein R and Y indicate the same groups as those indicated in the general formula (I).

The 1-chlorocarbonyl-5-fluorouracil used in this reaction can be obtained by introducing e.g. dichlorocarbonyl into 5-fluorouracil in a basic solvent. This solution can be used as it is at the next reaction with the amine (XV).

As the amine which is used in this process, 3-(3-aminopropyl)indole, 3-(6-aminoethyl)indole, 1-methyl-3-aminomethyl indole, 1-methyl-3-(2-aminoethyl)indole, 2-methyl-3-aminomethyl indole, 2-methyl-3-(2-aminoethyl)indole, 4-methoxy-3-aminomethyl indole, 4-methoxy-3-(2-aminoethyl)indole, 5-methoxy-3-aminomethyl indole, 5-methoxy-3-(2-aminoethyl)indole, 4,5-dimethoxy-3-aminomethyl indole, 4,5-dimethoxy-3-(2-aminoethyl)indole, 5,6-dimethoxy-3-aminomethyl indole, 5,6-dimethoxy-3-(2-aminoethyl)indole, 4,6-dimethoxy-3-aminomethyl indole, 4,6-dimethoxy-3-(2-aminoethyl)indole, 4,5,6-trimethoxy-3-aminomethyl indole, 4,5,6-trimethoxy-3-(2-aminoethyl)indole, 4-hydroxy-3-aminomethyl indole, 4-hydroxy-3-(2-aminoethyl)indole, 5-hydroxy-3-aminomethyl indole, 5-hydroxy-3-(2-aminoethyl)indole, 5,6-dihydroxy-3-aminomethyl indole, 5,6-dihydroxy-3-(2-aminoethyl)indole, 5-amino-3-aminomethyl indole, 5-amino-3-(2-aminoethyl)indole, 5-nitro-3-aminomethyl indole, 5-nitro-3-(2-aminoethyl)indole, 5-chloro-3-aminomethyl indole, 5-chloro-3-(2-aminoethyl)indole, etc. can be exemplified.

The ratio of 1-chlorocarbonyl-5-fluorouracil to the amine is preferably 1.5:1 to 1:1.5 by mole.

As the reaction solvent benzene, toluene, tetrahydrofuran, dioxane, acetonitrile, dimethyl formamide, dimethyl sulfoxide, ethyl acetate, chloroform etc. with basic solvent such as pyridine, triethylamine, etc. or the basic solvent alone can be used.

The reaction temperature range is 0-30°C, preferably, 5-15°C.

The reaction time is different by the reactivity of used amine, suitably from 0.5 to 5 hours.

As mentioned above, in these six processes, the residue obtained after distillation of a solvent under reduced pressure from the final result reactant, or the residue obtained by adding a suitable poor solvent is refined by extraction, recrystallization, chromatography, etc. to obtain the objective of this invention.

The compounds which can be the objective of this invention are exemplified:

5-fluoro-3,4-dihydro-2,4-dioxo-N-(2-thienyl)-1(2H)-pyrimidinecarboxamide,
 5-fluoro-3,4-dihydro-2,4-dioxo-N-(2-thiazolyl)-1(2H)-pyrimidinecarboxamide,
 5-fluoro-3,4-dihydro-2,4-dioxo-N-(1-oxopyridine-3-yl)-1(2H)-pyrimidinecarboxamide,
 5-fluoro-3,4-dihydro-2,4-dioxo-N-(3-indolyl)-1(2H)-pyrimidinecarboxamide,
 5-fluoro-3,4-dihydro-2,4-dioxo-N-(3-indolylmethyl)-1(2H)-pyrimidinecarboxamide,
 N-benzamidomethyl-5-fluoro-3,4-dihydro-2,4-dioxo-1(2H)-pyrimidinecarboxamide,
 5-fluoro-3,4-dihydro-2,4-dioxo-N-nicotinamidomethyl-1(2H)-pyrimidinecarboxamide,
 5-fluoro-3,4-dihydro-2,4-dioxo-N-[2-(1-pyridinio)ethyl]-1(2H)-pyrimidinecarboxamide chloride,
 5-fluoro-3,4-dihydro-2,4-dioxo-N-[3-(1-pyridinio)propyl]-1(2H)-pyrimidinecarboxamide chloride,
 5-fluoro-3,4-dihydro-2,4-dioxo-N-[7-(1-pyridinio)heptyl]-1(2H)-pyrimidinecarboxamide iodide,
 5-fluoro-3,4-dihydro-2,4-dioxo-N-(2-isocyanatoethyl)-1(2H)-pyrimidinecarboxamide,
 5-fluoro-3,4-dihydro-2,4-dioxo-N-(3-isocyanatopropyl)-1(2H)-pyrimidinecarboxamide,
 5-fluoro-3,4-dihydro-2,4-dioxo-N-(6-isocyanatohexyl)-1(2H)-pyrimidinecarboxamide,
 5-fluoro-3,4-dihydro-2,4-dioxo-N-(3-phenylureido)-1(2H)-pyrimidinecarboxamide,
 5-fluoro-3,4-dihydro-2,4-dioxo-N-[6-[3-(3-pyridinyl)ureido]hexyl]-1(2H)-pyrimidinecarboxamide,
 5-fluoro-3,4-dihydro-2,4-dioxo-N-[6-[3-(3-pyridyl)ureido]hexyl]-1(2H)-pyrimidinecarboxamide,
 5-fluoro-3,4-dihydro-2,4-dioxo-N-[6-[3-(4-sulfamoylphenyl)ureido]hexyl]-1(2H)-pyrimidinecarboxamide,
 5-fluoro-3,4-dihydro-2,4-dioxo-N-[6-(3-hexylureido)hexyl]-1(2H)-pyrimidinecarboxamide,
 5-fluoro-3,4-dihydro-2,4-dioxo-N-[6-[3-(3-dimethylaminopropyl)ureido]hexyl]-1(2H)-pyrimidinecarboxamide,
 5-fluoro-3,4-dihydro-2,4-dioxo-N-[3-(2-thiazolyl)ureido]hexyl-1(2H)-pyrimidinecarboxamide,
 N-[3-(2-diazolyl)ureido]hexyl-5-fluoro-3,4-dihydro-2,4-dioxo-N-1(2H)-pyrimidinecarboxamide,
 5-fluoro-3,4-dihydro-2,4-dioxo-N-[6-[3-nicotinamido-ureido]hexyl]-1(2H)-pyrimidinecarboxamide, and
 5-fluoro-3,4-dihydro-2,4-dioxo-N-[6-[3-isonicotinamido-ureido]hexyl]-1(2H)-pyrimidinecarboxamide.

It is found that the 5-fluorouracil derivatives of the objective of this invention are materials which has a property of antitumor or important intermediates which can be obtained the antitumor materials. The antitumor effect of these 5-fluorouracil derivatives is shown in Table 1. It is clearly from the Table that P-388 Leukemia of a laboratory mouse having a tumor is predominantly controlled.


The affects of this invention are as follows.

According to this invention, it is able to offer an anticancer medicine which has the anticancer effect and lower toxicity. Therefore, in comparison with the anticancer medicines of the prior art, the medicine obtained from a compound of this invention does not have a bad influence upon a living body. Furthermore, it does not have a problem that the medicine is hard on the stomach in case of oral administration. Then, when the medicine is produced by this invention method, purer object is obtained than that obtained by the conventional method.

The following examples illustrate this invention more specifically.

Example 1

5-Fluoro-3,4-dihydro-2,4-dioxo-N-(2-thienyl)-1(2H)-pyrimidinecarboxamide:



2-Thienyl isocyanate (3.09 g, 24.7 mmol) and 5-fluorouracil (3.21 g, 24.7 mmol) were added into a mixed solvent of benzene (50 ml) and pyridine (20 ml), and stirred and refluxed at 80 °C for 16 hours.


After cooling the reactant, obtained crystals were filtered, and washed with a mixed solvent of benzene : pyridine (3 : 2), subsequently washed with a mixed solvent of benzene : ethanol (3 : 2), and vacuum-dried. 5-Fluoro-3,4-dihydro-2,4-dioxo-N-(2-thienyl)-1(2H)-pyrimidinecarboxamide (5.00 g, 19.6 mmol) is obtained.

Yield : 79.3%, Melting point : 166 ~ 175 °C

IR_{max} (KBr disk) : 3430(N-H), 3090, 3050(=CH-), 1735, 1712(>=O), 1260(=CF-), 702(=C-S) [cm⁻¹]
 Element analysis : Found C 42.39, H 2.42, N 16.50 [%]
 Calculated [for C₉H₆FN₃O₃S] : C 42.35, H 2.37, N 16.46 [%]

5 Example 2

5-Fluoro-3,4-dihydro-2,4-dioxo-N-(1-oxopyridine-3-yl)-1(2H)-pyrimidinecarboxamide:



3-(1-Oxopyridyl)carbonyl azide (3.72 g, 22.7 mmol) and 5-fluorouracil (3.00 g, 23.1 mmol) were added into pyridine (45 ml), and stirred and reacted at 90 °C for one hour. After cooling the reactant, obtained crystals were filtered, washed with hot methanol, and vacuum-dried. 5-Fluoro-3,4-dihydro-2,4-dioxo-N-(1-oxopyridine-3-yl)-1(2H)-pyrimidinecarboxamide (5.48 g, 20.7 mmol) was obtained.

Yield : 91%, Melting point : 243 ~ 246 °C


IR_{max} (KBr disk) : 3460(NH), 3120, 3080 (=CH-), 1700 ~ 1760(>=O), 1280(N-O), 1250(=CF-) [cm⁻¹]

Element analysis : Found C 45.17, H 2.33, N 21.23 [%]

Calculated [for C₁₀H₆N₄O₄F] : C 45.29, H 2.28, N 21.13 [%]

Example 3

5-Fluoro-3,4-dihydro-2,4-dioxo-N-(3-indolyl)-1(2H)-pyrimidinecarboxamide:



3-Indolylcarbonyl azide (1.73 g, 9.29 mmol) and 5-fluorouracil (1.20 g, 9.23 mmol) were added into a mixed solvent of benzene (15 ml) and pyridine (3 ml), and stirred and refluxed at 80 °C for 24 hours.

After cooling the reactant, obtained crystals were filtered, washed with benzene, subsequently washed with hot methanol, and vacuum dried. 5-Fluoro-3,4-dihydro-2,4-dioxo-N-(3-indolyl)-1(2H)-pyrimidinecarboxamide (2.06 g, 7.15 mmol) was obtained.

Yield : 77% Melting point : 246 ~ 250 °C


IR_{max} (KBr disk) : 3430, 3370, 3340, 3200(NH), 3100 (=CH-), 1760, 1730, 1695(>=O), 1235(=CF-) [cm⁻¹]

Element analysis : Found C 53.99 H 2.96, N 19.39 [%]

Calculated [for C₁₃H₉N₄O₃F] : C 54.17, H 3.15, N 19.44 [%]

Example 4

5-Fluoro-3,4-dihydro-2,4-dioxo-N-(3-indolylmethyl)-1(2H)-pyrimidinecarboxamide:



3-Indolylacetohydrazide (6.90 g, 36.5 mmol) and concentrated hydrochloric acid (4.4 ml) were added into water (800 ml), and added sodium nitrite at 5 ~ 10°C. The obtained acid azide was extracted in benzene, washed with water, and dried with anhydrous sodium sulfate. The obtained solution was concentrated into about 100 ml. 5-Fluorouracil (4.70 g, 36.1 mmol) and pyridine (50 ml) were added into benzene solution of this acid azide, and stirred and refluxed at 80 °C for one hour.

After cooling the reactant, obtained crystals were filtered and washed with methanol. Subsequently, the crystals were dissolved into tetrahydrofuran, insoluble parts were removed, and then the obtained solution was concentrated under reduced pressure. The obtained crystals were washed with methanol, and vacuum-dried. 5-Fluoro-3,4-dihydro-2,4-dioxo-N-(3-indolylmethyl)-1(2H) pyrimidinecarboxamide (2.11 g, 6.98 mmol) was obtained.

Yield : 19%, Melting point : 176 ~ 177°C


IR_{max} (KBr disk) : 3440, 3300, 3200(NH), 3120 (=CH-), 1740, 1690 ~ 1720(>=O), 1235(=CF-) [cm⁻¹]

Element analysis : Found C 55.29 H 3.65, N 18.09 [%]

Calculated [for C₁₄H₁₁FN₄O₃] : C 55.59, H 3.67, N 18.60 [%]

Example 5

5-Fluoro-3,4-dihydro-2,4-dioxo-N-(3-indolylmethyl)-1(2H)-pyrimidinecarboxamide:



5-Fluorouracil (2.00 g, 15.4 mmol) was suspended into pyridine (60 ml). A little excess dichlorocarbonyl was blown into the suspension and stirred well at 0 ~ 5°C. After raising to 10°C, N₂ was blown into the reaction mixture, and nonreacted excess dichlorocarbonyl was removed. After recooling to 0 °C, 3-aminomethylindole (2.30 g, 15.7 mmol) in pyridine (20 ml) was dropped into the reactant.

After stirring the reactant and raising for one hour to the room temperature, the solvent was distilled under reduced pressure.

Chloroform (20 ml) and 1N hydrochloric acid (50 ml) were added into the residue. The obtained solids were washed with methanol, and vacuum-dried. 5-Fluoro-3,4-dihydro-2,4-dioxo-N-(3-indolylmethyl)-1(2H)-pyrimidinecarboxamide (1.63 g, 5.39 mmol) was obtained.

Yield : 35% Melting point : 176 ~ 178°C


IR_{max} (KBr disk) : 3440, 3300, 3200(NH), 3120 (=CH-), 1740, 1690 ~ 1720(>=O), 1235(=CF-) [cm⁻¹]

Element analysis : Found C 55.68 H 3.50, N 18.25 [%]

Calculated [for C₁₄H₁₁FN₄O₃] : C 55.59, H 3.67, N 18.60 [%]

Example 6

5-Fluoro-3,4-dihydro-2,4-dioxo-N-(5-fluoroindole-3-yl)methyl -1(2H)-pyrimidinecarboxamide:



5-Fluorouracil (6.10 g, 46.9 mmol) was suspended into pyridine (180 ml). A little excess dichlorocarbonyl was blown into the suspension stirring well at 0 ~ 5°C. After raising to 10°C, N₂ was blown into the reaction mixture, and nonreacted excess dichlorocarbonyl was removed. After recooling to 0°C, 5-fluoro-3-amino-methylindole (7.7 g, 46.9 mmol) in pyridine (50 ml) was dropped into the reactant.

After stirring the reactant and raising for one hour to the room temperature, the solvent was distilled under reduced pressure.

Water (100 ml) was added into the residue and stirred to obtain solids. The solids were washed with water and then chloroform, and dissolved in tetrahydrofuran. The solution was decolorized with active carbon, dried with anhydrous magnesium sulfate, and filtered. The filtrate was concentrated. 5-Fluoro-3,4-dihydro-2,4-dioxo-N-(5-fluoroindole-3-yl)methyl-1(2H)-pyrimidinecarboxamide (2.25 g, 7.03 mmol) was obtained.

Yield : 15%, Melting point : 162 ~ 166°C

¹H-NMR (CD₃SOCD₃-CD₃COCD₃-TMS): δ [ppm] ; 4.67(d; J=5.5Hz, -CH₂-, 2 H), 6.7 ~ 7.8(m; Ar-H, 4H), 8.3(brs; -NH-, 1H), 8.40(d; J=7.5Hz, -CF=CH-, 1H), 9.4(brs; -NH-, 1H), 11.0(brs; -NH-, 1H).


IR_{max} (KBr disk) [cm⁻¹] ; 3420, 3310(NH), 3100(=CH-), 1740, 1700, 1670 (>=O).

Element analysis : Found C 52.01, H 3.13, N 17.09 [%]

Calculated [for C₁₄H₁₀F₂N₄O₃] : C 52.51, H 3.15, N 17.49 [%]

Example 7

5-Fluoro-3,4-dihydro-2,4-dioxo -N- [2-(4,5,6-trimethoxyindole-3-yl)ethyl] -1(2H)-pyrimidinecarboxamide:



5-Fluorouracil (1.91 g, 14.7 mmol) was suspended into pyridine (80 ml). A little excess dichlorocarbonyl was blown into the suspension stirring well at 0 ~ 5°C. After raising to 10°C, N₂ was blown into the reaction mixture, and nonreacted excess dichlorocarbonyl was removed. After recooling to 0°C, 4,5,6-trimethoxy-3-(2-aminoethyl)indole (3.67 g, 14.7 mmol) in pyridine (20 ml) was dropped into the reactant.


After stirring the reactant and raising for one hour to the room temperature, the solvent was distilled under reduced pressure. The residue was washed with water, chloroform, and then methanol. 5-Fluoro-3,4-dihydro-2,4-dioxo -N- [2-(4,5,6-trimethoxyindole-3-yl)ethyl] -1(2H)-pyrimidinecarboxamide (1.29 g, 3.17 mmol) was obtained.

Yield : 22%, Melting point : 172 ~ 174°C

$^1\text{H-NMR}$ ($\text{CD}_3\text{SOCD}_3\text{-TMS}$) : δ [ppm] ; 3.00(t; $J=6\text{Hz}$, $-\text{CH}_2-$, 2H), 3.60(t; $J=6\text{Hz}$, $-\text{CH}_2-$, 2H), 3.70(s; $-\text{CH}_3$, 3H), 3.78(s; $-\text{CH}_3$, 3H), 3.90(s; $-\text{CH}_3$, 3H), 6.6~7.0(m; Ar-H, 2H), 8.35 (d; $J=7\text{Hz}$, $-\text{CF}=\text{CH}-$, 1H), 9.25(brs; $-\text{NH}-$, 1H) 10.53(brs; $-\text{NH}-$, 1H), 12.30(brs; $-\text{NH}-$, 1H).
 IR_{max} (KBr disk) [cm^{-1}] ; 3420(NH), 3100($=\text{CH}-$), 1740, 1700
 1675 ($>=0$), 1100(C-O-C).

Example 8

5-Fluoro-3,4-dihydro-2,4-dioxo -N- [1-ethoxycarbonyl-2-(3-indolyl)ethyl] -1(2H)-pyrimidinecarboxamide:



5-Fluorouracil (5.93 g, 45.6 mmol) was suspended into pyridine (100 ml). A little excess dichlorocarbonyl was blown into the suspension and stirred well at $0 \sim 5^\circ\text{C}$. After raising to 10°C , N_2 was blown into the reaction mixture, and nonreacted excess dichlorocarbonyl was removed. After recooling to 0°C , tryptophan ethyl ester (10.5 g, 45.2 mmol) in pyridine (50 ml) was dropped into the reactant.

After stirring the reactant and raising for 30 minutes to the room temperature, the solvent was distilled under reduced pressure. The obtained crystals were washed with methanol, and vacuum-dried. 5-Fluoro-3,4-dihydro-2,4-dioxo-N- [1-ethoxycarbonyl-2-(3-indolyl)ethyl] -1(2H)-pyrimidinecarboxamide (8.34 g, 21.5 mmol) was obtained.

Yield : 48%, Melting point : $250 \sim 258^\circ\text{C}$

$^1\text{H-NMR}$ ($\text{CD}_3\text{SOCD}_3\text{-TMS}$) : δ [ppm] ; 1.16 (t; $J=7\text{Hz}$, $-\text{CH}_3$, 3H), 3.15 ~ 3.5 (m; $-\text{CH}_2-$, 2H), 4.10(q; $J=7\text{Hz}$, $-\text{CH}_2-$, 2H), 4.5~5.0(m; $-\text{CH}-$, 1H), 6.8 ~ 7.65(m; Ar-H, $-\text{NH}-$, 6H), 8.37 (d; $J=7\text{Hz}$, $-\text{CF}=\text{CH}-$, 1H), 9.65(d; $J=6\text{Hz}$, $-\text{NH}-$, 1H), 10.92(brs; $-\text{NH}-$, 1H),


IR_{max} (KBr disk) [cm^{-1}] ; 3430, 3280 (NH), 1750, 1725, 1695 ($>=0$)

Element analysis : Found C 55.65, H 4.44, N 14.59 [%]

Calculated [for $\text{C}_{18}\text{H}_{17}\text{FN}_4\text{O}_5$] : C 55.67, H 4.41, N 14.43 [%]

Example 9

5-Fluoro-3,4-dihydro-2,4-dioxo -N- [2-(2-methylindole-3-yl) ethyl] -1(2H)-pyrimidinecarboxamide:



5-Fluorouracil (4.44 g, 34.1 mmol) was suspended into pyridine (150 ml). A little excess dichlorocarbonyl was blown into the suspension and stirred well at $0 \sim 5^\circ\text{C}$. After raising to 10°C , N_2 was blown into the reaction mixture, and nonreacted excess dichlorocarbonyl was removed. After recooling to 0°C , 2-methyl-3-(2-aminoethyl)indole (5.94 g, 34.1 mmol) in pyridine (150 ml) was dropped into the reactant.

After stirring the reactant and raising for one hour to the room temperature, the solvent was distilled under

reduced pressure. The residue was dissolved into methanol (30 ml) and 1 N HCl (100 ml) was added to the solution. After stirring the solution, viscous oil was obtained. After removing the supernatant liquid, chloroform (50 ml) was added into the oil to obtain crystals. The crystals were washed with water, methanol, and then chloroform, and dried under reduced pressure. 5-Fluoro-3,4-dihydro-2,4-dioxo-N-[2-(2-methylindole-3-yl)ethyl]-1(2H)-pyrimidinecarboxamide (2.94 g, 8.90 mmol) was obtained.

Yield : 26%, Melting point : 163 ~ 166°C

¹H-NMR (CD₃SOCD₃-TMS): δ [ppm] ; 2.37 (s; -CH₃, 3H), 2.94(t; J=6Hz, -CH₂-, 2H), 3.2 ~ 3.8 (m; -CH₂-, 2H), 6.83 ~ 7.70(m; Ar-H, -NH-, 5H), 8.34(d; J=7Hz, -CF=CH-, 1H), 9.32 (t; J=5Hz, -NH-, 1H), 10.65(brs; -NH-, 1H),


IR_{max} (KBr disk) [cm⁻¹] ; 3440, 3370, 3310, 3220(NH), 3120(=CH-), 1730, 1710 (>=O)

Element analysis : Found C 57.90, H 4.70, N 16.71 [%]

Calculated [for C₁₆H₁₅FN₄O₃] : C 58.18, H 4.58, N 16.96 [%]

Example 10

5-Fluoro-3,4-dihydro-2,4-dioxo-N-(5-methoxyindole-3-yl) methyl-1 (2H)-pyrimidinecarboxamide:



5-Fluorouracil (2.93 g, 22.5 mmol) was suspended into pyridine (90 ml). A little excess dichlorocarbonyl was blown into the suspension and stirred well at 0 ~ 5°C. After raising to 10°C, N₂ was blown into the reaction mixture, and nonreacted excess dichlorocarbonyl was removed. After recooling to 0°C, 5-methoxy-3-amino-methylindole (3.97 g, 22.5 mmol) in pyridine (30 ml) was dropped into the reactant.

After stirring the reactant and raising for one hour to the room temperature, the solvent was distilled under reduced pressure. To the residue 20 ml of chloroform and 70 ml of 1 N HCl were added. After stirring the solution, crystals were obtained. The crystals were washed with water and then methanol. 5-Fluoro-3,4-dihydro-2,4-dioxo-N-(5-methoxyindole-3-yl)methyl-1 (2H)-pyrimidinecarboxamide (3.33 g, 10.0 mmol) was obtained.

Yield : 44%, Melting point : 145 ~ 151°C

¹H-NMR (C₅D₅N-TMS): δ [ppm] ; 3.83 (s; -OCH₃-, 3H), 4.95(d; J=5Hz, -CH₂-, 2H), 6.86 ~ 7.60(m; Ar-H, 4H), 8.62(d; J=7Hz, -CF=CH-, 1H), 8.93(brs; -NH-, 1H), 8.87(t; J=5Hz, -NH-, 1H), 11.73(brs; -NH-, 1H),


IR_{max} (KBr disk) [cm⁻¹] ; 3440, 3320, 3210(NH), 3100(=CH-), 1740, 1720 ~ 1670 (>=O)

Element analysis : Found C 54.29, H 3.93, N 16.57 [%]

Calculated [for C₁₅H₁₃FN₄O₄] : C 54.22, H 3.94, N 16.86 [%]

Example 11

5-Fluoro-3,4-dihydro-2,4-dioxo-N-(5-chloroindole-3-yl)methyl-1(2H)-pyrimidinecarboxamide:



5-Fluorouracil (5.53 g, 42.5 mmol) was suspended into pyridine (160 ml). A little excess dichlorocarbonyl was blown into the suspension and stirred well at 0 ~ 5°C. After raising to 10°C, N₂ was blown into the reaction mixture, and nonreacted excess dichlorocarbonyl was removed. After recooling to 0°C, 5-chloro-3-aminomethylindole (7.67 g, 42.5 mmol) in pyridine (30 ml) was dropped into the reactant.

After stirring the reactant and raising for one hour to the room temperature, the solvent was distilled under reduced pressure. The residue was dissolved into methanol (50 ml), and then 1 N HCl (50 ml) was added. After stirring the solution, solids were obtained. The solids were washed with water and dissolved in ethyl ether. The solution was decolorized with active carbon, dried with anhydrous sodium sulfate, and filtered. The filtrate was concentrated. The obtained crystals were dissolved in ethyl ether. Insoluble parts were filtered. Hexane was added into the filtrate, and crystals were obtained. 5-Fluoro-3,4-dihydro-2,4-dioxo-N-(5-chloroindole-3-yl)methyl-1(2H)-pyrimidinecarboxamide (1.10 g, 3.27 mmol) was obtained.

Yield : 8%, Melting point : 101 ~ 105°C

¹H-NMR (CD₃COCD₃-TMS): δ [ppm] ; 4.70(d; J=5.5Hz, -CH₂-, 2H), 6.8 ~ 7.8(m; Ar-H, 4H), 8.42 (d; J=7Hz, -CF=CH-, 1H), 8.5(brs; -NH-, 1H), 10.05(brs; -NH-, 1H).


IR_{max} (KBr disk) [cm⁻¹] ; 3440, 3350(NH), 3100(=CH-), 1745, 1700, 1680 (>=O).

Element analysis : Found C 50.34, H 3.32, N 16.35 [%]

Calculated [for C₁₄H₁₀ClFN₄O₃] : C 49.94, H 2.99, N 16.64 [%]

Example 12

5-Fluoro-3,4-dihydro-2,4-dioxo -N- [2-(5-chloroindole-3-yl) ethyl] -1(2H)-pyrimidinecarboxamide:



5-Fluorouracil (4.08 g, 31.4 mmol) was suspended into pyridine (120 ml). A little excess dichlorocarbonyl was blown into the suspension and stirred well at 0 ~ 5°C. After raising to 10°C, N₂ was blown into the reaction mixture, and nonreacted excess dichlorocarbonyl was removed. After recooling to 0°C, 5-chloro-3-(2-aminoethyl)indole (6.11 g, 31.4 mmol) in pyridine (30 ml) was dropped into the reactant.


After stirring the reactant and raising for one hour to the room temperature, the solvent was distilled under reduced pressure. The residue was dissolved into chloroform, and then 0.5 N HCl (50 ml) was added. After stirring the solution, insoluble matter was separated. This insoluble matter was washed with water and then chloroform, and dissolved in tetrahydrofuran. The solution was decolorized with active carbon, dried with anhydrous magnesium sulfate, and filtered. The filtrate was passed through a short column of silica gel. Then, the obtained solution was concentrated to about 50 ml and added hexane (20 ml). The obtained crystals were washed with methanol. 5-Fluoro-3,4-dihydro-2,4-dioxo -N- [2-(5-chloroindole-3-yl) ethyl] -1(2H)-pyrimidinecarboxamide (2.79 g, 7.95 mmol) was obtained.

Yield : 25%, Melting point : 204 ~ 206°C

¹H-NMR (CD₃SOCD₃-CD₃COCD₃-TMS): δ [ppm] ; 3.00(t; J=6Hz, -CH₂-, 2H), 3.60(t; J=6Hz, -CH₂-, 2H), 6.9 ~ 7.8(m; Ar-H, -NH-, 5H), 8.38 (d; J=7Hz, -CF=CH-, 1H), 9.25(brs; -NH-, 1H), 11.0(brs; -NH-, 1H)
 IR_{max} (KBr disk) [cm⁻¹] ; 3450, 3320(NH), 3100(=CH-), 1750, 1700, 1670 (>=O).
 Element analysis : Found C 51.56, H 3.50, N 15.47 [%]
 Calculated [for C₁₅H₁₂ClFN₄O₃] : C 51.37, H 3.45, N 15.97 [%]

Example 13

N-Benzamidomethyl-5-fluoro-3,4-dihydro-2,4-dioxo-1(2H) pyrimidinecarboxamide:



Benzamidoacetyl azide (7.30 g, 35.8 mmol) and 5-fluorouracil (3.90 g, 30.0 mmol) were added into benzene (20 ml) and pyridine (5 ml), and stirred and refluxed at 80°C for 6 hours.

After cooling the reactant, obtained crystals were filtered, washed with chloroform, subsequently washed with methanol, and vacuum -dried. N-Benzamidomethyl-5-fluoro-3,4-dihydro-2,4-dioxo-1(2H)-pyrimidinecarboxamide (6.77 g, 22.1 mmol) was obtained.

Yield : 74%, Melting point : 196 ~ 199°C


IR_{max} (KBr disk) : 3425, 3330, 3230(NH), 3125 (=CH-), 1750, 1735(>=O), 1240(=CF-) [cm⁻¹]

Element analysis : Found C 50.98 H 3.44, N 18.25 [%]

Calculated [for C₁₃H₁₁N₄O₄F] : C 50.98, H 3.62, N 18.29 [%]

Example 14

5-Fluoro-3,4-dihydro-2,4-dioxo -N- [2-(1-pyridinio)ethyl] -1(2H)-pyrimidinecarboxamide chloride:



2-Chloroethyl isocyanate (4.71 g, 44.6 mmol) and 5-fluorouracil (5.80 g, 44.6 mmol) were added into pyridine (50 ml), and stirred and refluxed at 90 °C for 3.5 hours.

After cooling the reactant, obtained crystals were filtered, washed with chloroform, subsequently washed with methanol, and vacuum -dried. 5-Fluoro-3,4-dihydro-2,4-dioxo -N- [2-(1- pyridinio)ethyl] -1(2H)-pyrimidinecarboxamide chloride (2.38 g, 7.56 mmol) was obtained.

Yield : 17%, Melting point : 212 ~ 216°C


IR_{max} (KBr disk) : 3430, 3350, 3270(NH), 3100, 3045 (=CH-), 1700 ~ 1740, 1690(>=O), 1260(=CF-) [cm⁻¹]

Element analysis : Found C 45.33, H 3.98, N 17.56 [%]

Calculated [for C₁₂H₁₂ ClF N₄O₃] : C 45.80, H 3.84, N 17.80 [%]

Example 15

5-Fluoro-3,4-dihydro-2,4-dioxo -N- [2-(1-pyridinio)ethyl] -1(2H)-pyrimidinecarboxamide chloride:



N-(2-Chloroethyl)-5-fluoro-3,4-dihydro-2,4-dioxo-1(2H)-pyrimidinecarboxamide (2.00 g, 8.49 mmol) were added into pyridine (10 ml), and stirred and refluxed at 90 °C for 6 hours.

After cooling the reactant, obtained crystals were filtered, washed with chloroform, subsequently washed with methanol, and vacuum -dried. 5-Fluoro-3,4-dihydro-2,4-dioxo -N- [2-(1- pyridinio) ethyl] -1(2H)-pyrimidinecarboxamide chloride (1.36 g, 4.32 mmol) was obtained.

Yield : 51%, Melting point : 213 ~ 216 °C


IR _{max} (KBr disk) : 3430, 3350, 3270(NH), 3100, 3045 (=CH-), 1700 ~ 1740, 1690(>=O), 1260(=CF-) [cm⁻¹]

Element analysis : Found C 45.53 H 4.07, N 17.68 [%]

Calculated [for C₁₂H₁₂ClFN₄O₃] : C 45.80, H 3.84, N 17.80 [%]

Example 16

5-Fluoro-3,4-dihydro-2,4-dioxo -N- [5-(1-pyridinio)pentyl] -1(2H)-pyrimidinecarboxamide bromide:



5-Bromopentyl isocyanate (3.00 g, 15.6 mmol) and 5-fluorouracil (2.04 g, 15.7 mmol) were added into pyridine (25 ml), and the mixture was stirred and refluxed at 80 °C to 100 °C for 3 hours.

After cooling the reactant, the residue obtained under reduced pressure was washed with chloroform, and vacuum-dried. 5-Fluoro-3,4-dihydro-2,4-dioxo -N- [5-(1-pyridinio)pentyl] -1(2H)-pyrimidinecarboxamide bromide (3.68 g, 9.17 mmol) was obtained.

Yield : 59%, Melting point : 132 ~ 135 °C


IR _{max} (KBr disk) : 3430, 3300(NH), 3060(=CH-), 2950, 2860(C-H), 1755, 1720, 1675(>=O), 1245 (=CF-) [cm⁻¹]

Element analysis : Found C 44.73, H 4.57, N 13.25 [%]

Calculated [for C₁₅H₁₈BrFN₄O₃] : C 44.90, H 4.52, N 13.96 [%]

Example 17

5-Fluoro-3,4-dihydro-2,4-dioxo -N- [3-(1-pyridinio) propyl] -1(2H)-pyrimidinecarboxamide chloride:



3-Chloropropyl isocyanate (2.71 g, 22.7 mmol) and 5-fluorouracil (2.95 g, 22.7 mmol) were added into pyridine (20 ml), and stirred and refluxed at 90 °C for 3 hours.

After cooling the reactant, benzene was added. The obtained crystals were filtered, and washed with benzene, and then with chloroform. 5-Fluoro-3,4-dihydro-2,4-dioxo-N- [3-(1-pyridinio)propyl] -1(2H)-pyrimidinecarboxamide chloride (2.82 g, 8.58 mmol) was obtained.

Yield : 38%, Melting point : 80 ~ 105°C


IR_{max} (KBr disk) : 3440(NH), 3130, 3070 (=CH-), 1710 ~ 1750, 1640 ~ 1710(>=O), 1245(=CF-) [cm⁻¹]

Element analysis : Found C 47.38, H 4.66, N 16.44 [%]

Calculated [for C₁₃H₁₄ClFN₄O₃] : C 47.50, H 4.29, N 17.04 [%]

Example 18

5-Fluoro-3,4-dihydro-2,4-dioxo -N- {6- [3-(3-pyridyl)ureido] hexyl } -1(2H)-pyrimidinecarboxamide:



1,6-Hexamethylene diisocyanate (1.29 g, 7.67 mmol) was added into pyridine (20 ml). 5-Fluorouracil (1.00 g, 7.69 mmol) was added into the solution little by little for 20 minutes. Then the mixture was stirred and reacted at 90 °C for one hour.

After cooling the reactant, the residue obtained under reduced pressure was dissolved into chloroform, and insoluble parts were removed. Thus obtained solution of the derivative having an isocyanate group was concentrated to about 10 ml. 3-Aminopyridine (0.72 g, 7.65mmol) was added into the solution. After dissolving, the mixture was refluxed for one minute.

After cooling the reactant, obtained crystals were filtered, washed with chloroform, then washed with hot acetonitrile and vacuum-dried. 5-Fluoro-3,4-dihydro-2,4-dioxo-N- {6- [3-(3-pyridyl) ureido] hexyl } -1(2H)-pyrimidinecarboxamide (1.41 g, 3.59 mmol) was obtained

Yield : 47%, Melting point : 180 ~ 183°C


R_{max} (KBr disk) : 3400, 3330(NH), 3100 (=CH-), 2940, 2850(C-H), 1740, 1695 1665(>=O), 1230(=CF-) [cm⁻¹]

Element analysis : Found C 52.97, H 5.55, N 21.48 [%]

Calculated [for C₁₇H₂₁FN₆O₄] : C 52.04, H 5.39, N 21.42 [%]

Example 19

5-Fluoro-3,4-dihydro-2,4-dioxo -N- {6- [3-(2-pyridyl)ureido] hexyl } -1(2H)-pyrimidinecarboxamide:



1,6-Hexamethylene diisocyanate (2.59 g, 15.4 mmol) was added into pyridine (30 ml). 5-Fluorouracil (2.00 g, 15.4 mmol) was added into the solution little by little for 30 minutes. Then, the mixture was stirred and reacted at 90 °C for one hour.

After cooling the reactant, the residue obtained under reduced pressure was dissolved into chloroform, then insoluble parts were removed and concentrated to about 15 ml. 2-Aminopyridine (1.45 g, 15.4 mmol) was added into thus obtained solution of the derivative having an isocyanate group and stirred at room temperature for 10 minutes. The obtained crystals were removed. After concentrating the filtrate, obtained crystals were washed with chloroform and vacuum-dried. 5-Fluoro-3,4 dihydro-2,4-dioxo-N- {6- [3-(2-pyridyl)ureido] hexyl } -1(2H)-pyrimidinecarboxamide (1.81 g, 4.61mmol) was obtained.

Yield : 30%, Melting point : 177 ~ 181°C


IR max (KBr disk) : 3450, 3410, 3300(NH), 3050(=CH-), 2940, 2850(C-H), 1740, 1690, 1675(>=O), 1230(=CF-) [cm⁻¹]

Element analysis : Found C 52.33, H 5.49, N 20.72 [%]

Calculated [for C₁₇H₂₁FN₆O₄] : C 52.04, H 5.39, N 21.42 [%]

Example 20

5-Fluoro-3,4-dihydro-2,4-dioxo-N- {6- [3-(4-sulfamoylphenyl)ureido] hexyl } -1(2H)-pyrimidinecarboxamide:



1,6-Hexamethylene diisocyanate (2.59 g, 15.4 mmol) was added into benzene (25 ml) and the solution was refluxed. 5-Fluorouracil (2.00 g, 15.4 mmol) dissolved in pyridine (20 ml) was added into the solution little by little for 20 minutes. Then, the mixture was stirred and reacted for one hour.

After cooling the reactant, the residue obtained under reduced pressure was dissolved into chloroform, and then insoluble parts were removed. The filtrate was concentrated, and the residue was washed with hexane. Tetrahydrofuran (20 ml) was added into the obtained crude material of derivative containing isocyanate group to dissolve, and sulfanilamide (2.63 g, 15.3mmol) was added to the solution. The mixture was refluxed for one hour. After cooling, the reactant was concentrated under reduced pressure, and chloroform was added. The obtained crystals were filtered, washed with chloroform and then acetone. Hot methanol was added into the crystals to dissolve the crystals and to remove insoluble materials. The filtrate was washed and vacuum-dried. 5-Fluoro-3,4-dihydro-2,4-dioxo-N- {6- [3-(4-sulfamoylphenyl)ureido] hexyl } -1(2H)-pyrimidinecarboxamide (1.08 g, 3.20 mmol) was obtained.

Yield : 15%, Melting point : 181 ~ 184°C


IR max (KBr disk) : 3400, 3350, 3260(NH), 3130(=CH), 2960, 2890(C-H), 1750, 1710, 1685(>=O), 1340, 1160(SO₂), 1240(=CF-) [cm⁻¹]

Element analysis : Found C 46.37, H 5.24, N 17.32 [%]

Calculated [for C₁₈H₂₃FN₆O₆S] : C 45.95, H 4.93, N 17.86 [%]

Example 21

5-Fluoro-3,4-dihydro-2,4-dioxo -N- {6- [3- (3 dimethylaminopropyl)ureido] hexyl }
-1(2H)-pyrimidinecarboxamide:



1,6-Hexamethylene diisocyanate (2.59 g, 15.4 mmol) was added into pyridine (25 ml). 5-Fluorouracil (2.00 g, 15.4 mmol) was added into the solution little by little for 20 minutes at 90 °C. Then, the mixture was stirred and reacted for one hour.

After cooling the reactant, the residue obtained under reduced pressure was dissolved into chloroform, and insoluble parts were removed. The filtrate was concentrated to about 10 ml. N,N-Dimethyl-1,3-propanediamine (1.57 g, 15.4 mmol) was added into the obtained solution of derivative having isocyanate group, and the mixture was stirred and reacted for 10 hours at room temperature. After concentrating the solution under reduced pressure, chloroform was added into the obtained residue. The separated viscous material was washed with chloroform and vacuum-dried. 5-Fluoro-3,4-dihydro-2,4-dioxo-N- {6- [3-(3-dimethylaminopropyl)ureido] hexyl } -1(2H)-pyrimidinecarboxamide (4.20 g, 10.5 mmol) was obtained.

Yield : 68%, Melting point : 70 ~ 80 °C


IR_{max} (KBr disk) : 3420(NH), 3120(=CH-), 2960, 2880(C-H), 1740, 1690(>=O), 1250(=CF-) [cm⁻¹]

Element analysis : Found C 50.41, H 7.06, N 19.36 [%]

Calculated [for C₁₇H₂₉FN₆O₄] : C 50.99, H 7.30, N 20.99 [%]

Example 22

5-Fluoro-3,4-dihydro-2,4-dioxo -N- {6- [3-nicotinamido-ureido] hexyl } -1(2H)-pyrimidinecarboxamide



1,6-Hexamethylene diisocyanate (2.59 g, 15.4 mmol) was added into pyridine (25 ml). 5-Fluorouracil (2.00 g, 15.4 mmol) was added into the solution little by little for 20 minutes at 90 °C. Then, the mixture was stirred and reacted for one hour.

After cooling the reactant, the residue obtained under reduced pressure was dissolved into chloroform, and insolubles were removed. The filtrate was concentrated to about 10 ml. Nicotinoylhydrazide (2.10 g, 15.3 mmol) was added into the obtained filtrate and the mixture was refluxed for 20 minutes. After cooling, crystals were filtered. The obtained crystals were washed with chloroform, and vacuum-dried. 5-Fluoro-3,4-dihydro-2,4-dioxo-N- {6-[3-nicotinamidoureido] hexyl } -1(2H)-pyrimidinecarboxamide (2.05 g, 4.71 mmol) was obtained.

Yield : 31%, Melting point : 138 ~ 147 °C



IR_{max} (KBr disk) : 3200 ~ 3400(NH), 3100 (=CH-), 2940, 2860(C-H), 1740, 1700, 1660(>=O), 1250(=CF-) [cm⁻¹]

Element analysis : Found C 50.33, H 5.39, N 22.88 [%]

Calculated [for C₁₈H₂₂FN₇O₅] : C 50.82, H 5.21, N 23.05 [%]

Example 23

5-Fluoro-3,4-dihydro-2,4-dioxo -N- {6- [3-isonicotinamido-ureido] hexyl } -1(2H)-pyrimidinecarboxamide



1,6-Hexamethylene diisocyanate (2.59 g, 15.4 mmol) was added into pyridine (25 ml). 5-Fluorouracil (2.00 g, 15.4 mmol) was added into the solution little by little for 20 minutes at 90 °C. Then, the mixture was stirred and reacted at 90 °C for one hour.

After cooling the reactant, the residue obtained under reduced pressure was dissolved into chloroform, and insolubles were removed. The filtrate was concentrated to about 10ml. Isonicotinoylhydrazide (2.10 g, 15.3 mmol) was added into the obtained filtrate and the mixture was refluxed for 30 minutes. After cooling, crystals were filtered. The obtained crystals were washed with hot methanol, and hot pyridine was added to dissolve the crystals. The resulting insolubles were removed and the filtrate was concentrated under reduced pressure. The obtained crystals were washed with methanol and vacuum-dried. 5-Fluoro-3,4-dihydro-2,4-dioxo-N- {6- [3-isonicotinamidoureido] hexyl } -1(2H)-pyrimidinecarboxamide (1.56 g, 3.58 mmol) was obtained.

Yield : 23%, Melting point : 185 ~ 197 °C



IR max (KBr disk) : 3400, 3300(NH), 3100(=CH-), 2940, 2860(C-H), 1745, 1700, 1670(>=O), 1250(=CF-) [cm⁻¹]

Element analysis : Found C 50.72, H 5.17, N 23.24 [%]

Calculated [for C₁₈H₂₂FN₇O₅] : C 50.82, H 5.21, N 23.05 [%]

Example 24

5-Fluoro-3,4-dihydro-2,4-dioxo -N- {6- [3-(quinoline-3-yl) ureido] hexyl } -1(2H)-pyrimidinecarboxamide



1,6-Hexamethylene diisocyanate (3.87 g, 23.0 mmol) was added into pyridine (60 ml). 5-Fluorouracil (2.98 g, 22.9 mmol) was added into the solution little by little for 30 minutes. Then, the mixture was stirred and reacted at 90 °C for one hour.

After cooling the reactant, the residue obtained under reduced pressure was dissolved into chloroform, and insolubles were removed. The filtrate was concentrated to about 30 ml. 3-Aminoquinoline (3.32 g, 23.0 mmol) was added into the obtained filtrate and the mixture was refluxed for 30 minutes. The obtained crystals were filtered and washed with hot acetonitrile and vacuum-dried. 5-Fluoro-3,4-dihydro-2,4-dioxo-N- {6- [3-(quinoline-3-yl) ureido] hexyl } -1(2H)-pyrimidinecarboxamide (6.20 g, 14.0 mmol) was obtained.

Yield : 61%, Melting point : 190 ~ 195 °C


IR max (KBr disk) : 3400, 3300(NH), 3040(=CH-), 1740, 1705, 1680(>=O), 1260(=CF-) [cm⁻¹]

Element analysis : Found C 57.30, H 5.52, N 18.40 [%]

Calculated [for C₂₁H₂₃FN₆O₄] : C 57.01, H 5.24, N 18.99 [%]

Example 25

5-Fluoro-3,4-dihydro-2,4-dioxo -N- {6- [3-(benzothiazole-2-yl)ureido] hexyl } -1(2H)-pyrimidinecarboxamide




1,6-Hexamethylene diisocyanate (3.76 g, 22.4 mmol) was added into pyridine (60 ml). 5-Fluorouracil (2.98 g, 22.9 mmol) was added into the solution little by little for 30 minutes at 90 °C. Then, the mixture was stirred and reacted at 90 °C for one hour.

After cooling the reactant, the residue obtained under reduced pressure was dissolved into chloroform, and insolubles were removed. The filtrate was concentrated to about 30 ml. 2-Aminobenzothiazole (3.35 g, 22.3 mmol) was added into the obtained filtrate which contained an isocyanate derivative, and the mixture was refluxed for one hour. After cooling, crystals were filtered. The obtained crystals were washed with methanol and vacuum-dried. 5-Fluoro-3,4-dihydro-2,4-dioxo-N- {6- [3-(benzothiazole-2-yl) ureido] hexyl } -1(2H)-pyrimidinecarboxamide (4.04 g, 9.02 mmol) was obtained. Yield : 40%, Melting point : 256 ~ 262°
 IR max (KBr disk) : 3380, 3275(NH), 3180, 3050(=CH-), 1750, 1720, 1690(>=O), 1260(=CF-) [cm⁻¹]
 Element analysis : Found C 50.68, H 4.96, N 19.00 [%]
 Calculated [for C₁₉H₂₁N₆O₄S] : C 50.89, H 4.72, N 18.74 [%]

Example 26

5-Fluoro-3,4-dihydro-2,4-dioxo-N-pyridinimethyl-1(2H) pyrimidinecarboxamide chloride:



Chloromethyl isocyanate (10.6 g, 116 mmol) and 5-fluorouracil (7.56 g, 58.2 mmol) were added into pyridine (100 ml). Then, the mixture was stirred and reacted under reflux for 15 minutes. After cooling the reactant, the obtained crystals were washed with pyridine, and then toluene, and vacuum-dried. 5-Fluoro-3,4-dihydro-2,4-dioxo-N-pyridinimethyl-1(2H)-pyrimidinecarboxamide chloride (17.0 g, 56.5 mmol) was obtained.

Yield : 97%, Melting point : 171 ~ 177°C
 IR max (KBr disk) : 3300(NH), 3100, 3055(=CH-), 1765, 1730, 1685(>=O), 1255(=CF-) [cm⁻¹]
 Element analysis : Found C 43.72, H 3.62, N 18.90 [%]
 Calculated [for C₁₁H₁₀FCIN₄O₃] : C 43.94, H 3.35, N 18.63 [%]

[Antitumor Effect Test]

Leukosis cells of P-388 mouse of 1x10⁶ /mouse were grafted into the abdomen of CDF₁ or BDF₁ mouse, and the fixed quantity of the compound of this invention was successively dosed into the abdomen for 5 days.

Each 6 mice per dose level as test groups and 30 ~ 33 mice as control groups were used. Effect of antitumor was decided by the ration of survival days (T/C), the result is shown in Table 1.

The ratio of survival days (T/C)

$$= \frac{\text{Average survival day of dosed groups}}{\text{Average survival day of control groups}} \times 100 (\%)$$

Table 1

Dosed compound(1)	Dose mg/kg	T/C %	Dosed compound(1)	Dose mg/kg	T/C %
Experiment 1	240 120 60 30	152 129 152 124 138 137 129 129	Experiment 17	120 60 30 15	161 120 138 131 130 115
Experiment 2	120 60 30 15	128 92 165 175 149 127	Experiment 18	15 7.5 3.75 1.87 0.94 0.47	139 138 131 124 115 110
Experiment 3	400 240 120 60 30	153 170 142 136 128 135 117 123 116	Experiment 19	240 120 60 30	198 109 164 160 154 151
Experiment 4	400 240 120 60 30	128 143 111 118 111 115 117	Experiment 20	240 120 60 30	112 102 111 96 110 95
Experiment 13	120 60 30	147 132 132 115 117 103	Experiment 21	60 30 15	120 142 123 120
Experiment 14	120 60 30 15	215 212 171 169	Experiment 22	400 240 120 60 30 15	127 140 99 128 115 113 126 113
Experiment 16	30 15 7.5	120 120 112	Experiment 23	240 120 60 30	138 123 124 115 119 109

[Acute Toxicity Test]

LD₅₀ measured by dosing the compounds which was obtained by each experiment are shown in Table 2.


Table 2

Dosed Compound	LD ₅₀ (mg/kg)	Dosed Compound	LD ₅₀ (mg/kg)
Experiment 1	> 240	Experiment 17	240
2	240	18	> 30
3	> 400	19	> 240
4	> 400	20	> 240
13	240	21	120
14	120	22	> 400
16	60	23	> 240

This invention is applied to the field of medicine, especially anticancer medicine. 5-fluorouracil derivatives of this invention and the processes for producing thereof are new compounds and processes, so the resulting derivatives will be used in the field of pharmaceutical such as medical supplies, agricultural chemicals and so on, or these intermediates.


Claims

(1). A 5-fluorouracil derivative represented by a general formula:



wherein R indicates a non-substituted or substituted alkylene group having 0-10 carbon atoms, A indicates an atomic group of -NH and -CO-, n is 0 or 1, and Y indicates a non-substituted or substituted alkyl group having 1-10 carbon atoms, a non-substituted or substituted aryl group, a non-substituted or substituted heteroaryl group, a pyridinium ion having a halogen as a pair ion or an isocyanate group.


(2). A derivative as claimed in claim 1, characterized in that the general formula (I) is represented by a general formula:



wherein Y indicates a non-substituted or substituted aryl group or a non-substituted or substituted


heteroaryl group, and R, A and n are the same as those indicated in the general formula (I).

(3). A derivative as claimed in claim 1, characterized in that the general formula (I), wherein Y indicates a pyridinium ion having a halogen as a pair ion and n is 0, is represented by a general formula:




wherein R has the same meaning as in the general formula (I) and X indicates Cl, Br or I.

(4). A derivative as claimed in claim 1, characterized in that the general formula (I), wherein Y indicates an isocyanate group and n is 0, is represented by a general formula:




wherein R has the same meaning in the general formula (I).

(5). A derivative as claimed in claim 1, characterized in that the general formula (I), wherein A indicates a -NHCO-, -NHCONH- or -NHCONHNNHCO-, n is 1, Y indicates a non-substituted or substituted alkyl group having 1-10 carbon atoms, a non-substituted or substituted aryl group, a non-substituted or substituted heteroaryl group, is represented by a general formula:



wherein R has the same meaning in the general formula (I).

(6). A derivative as claimed in claim 1, characterized in that the general formula (I), wherein n is 0 and Y indicates a non-substituted or substituted 3-indolyl group, is represented by a general formula:



wherein R has the same meaning in the general formula (I), and R¹, R², R³, R⁴, R⁵ and R⁶ indicate


hydrogen, a hydroxyl group, an amino group, a nitro group, a halogen atom, or a non-substituted or substituted alkyl, alkoxy, aralkyl, aralkyloxy, acyl or acyloxy group having 1-10 carbon atoms, respectively.

(7). A derivative as claimed in claim 6, characterized in that R^1 , R^2 , R^3 , R^4 , R^5 and R^6 of the general formula (VI) indicate hydrogen, or a non-substituted or substituted alkyl or aralkyl group having 1-10 carbon atoms, respectively.

(8). A derivative as claimed in claim 6, characterized in that at least one of R^3 , R^4 , R^5 and R^6 of the general formula (VI) indicate a hydroxyl group, an amino group, a nitro group, a halogen atom, or a non-substituted or substituted alkyloxy, aralkyloxy or acyloxy group having 1-10 carbon atoms.


(9). A derivative as claimed in claim 6, characterized in that R^1 of the general formula (VI) indicate a non-substituted or substituted acyl group having 1-10 carbon atoms.

(10). A process for producing a 5-fluorouracil derivative of claim 1, which comprises: reacting 5-fluorouracil and an isocyanate represented by a general formula:




wherein R, A, n and Y are the same as those indicated in the formula (I).

(11). A process for producing a 5-fluorouracil derivative of claim 1, which comprises: reacting 5-fluorouracil and a carboxylic acid azide represented by a general formula:




wherein R, A, n and Y are the same as those indicated in the formula (I).

(12). A process as claimed in claim 10, characterized in that the isocyanate is represented by a general formula:




wherein R is one of the same groups as the groups indicated in the formula (I).


(13). A process for producing a 5-fluorouracil derivative represented by a general formula:



wherein R indicates a non-substituted or substituted alkylene group having 0-10 carbon atoms, Y indicates a non-substituted or substituted alkyl group having 1-10 carbon atoms, a non-substituted or substituted aryl group, a non-substituted or substituted heteroaryl group, a pyridinium ion having a halogen as a pair ion or an isocyanate group, and Z indicates -NH- or -NHNH-CO- group, characterized by reacting a 5-fluorouracil derivative represented by a formula:




wherein R indicates a non-substituted or substituted alkylene group having 0-10 carbon atoms, and a compound represented by a general formula:



wherein Y and Z are the same as those indicated in the formula (XI).

(14). A process for producing a 5-fluorouracil derivative of claim 3, which comprises: reacting 5-fluorouracil derivative represented by a general formula (XII) and pyridine:




(X II)




wherein R and X are the same groups as the groups indicated in the formula (III).

(15). A process for producing a 5-fluorouracil derivative of claim 3, which comprises: reacting 5-fluorouracil and a halogenoisocyanate represented by a general formula (X III) and pyridine:



wherein R and X are the same as those indicated in the formula (III).


(16). A process for producing a 5-fluorouracil derivative represented by a general formula:




(X VI)




wherein R indicates a non-substituted or substituted alkylene group having 0-10 carbon atoms, and Y indicates a non-substituted or substituted alkyl group having 1-10 carbon atoms, a non-substituted or substituted aryl group, a non-substituted or substituted heteroaryl group, a pyridinium ion having a halogen as a pair ion or an isocyanate group, characterized by reacting 1-chlorocarbonyl-5 fluorouracil represented by a formula:



(X IV)




and a compound represented by a general formula:



wherein R and Y are the same groups as the groups indicated in the formula (X VI).


(17). A process for producing a 5-fluorouracil derivative of claim 6, which comprises: reacting 5-fluorouracil and an isocyanate represented by a general formula:



(X VI)


wherein R, R¹, R², R³, R⁴, R⁵ and R⁶ indicate the same groups as the groups indicated in the general formula (VI).

(18). A process for producing a 5-fluorouracil derivative of claim 6, which comprises: reacting 5-fluorouracil and a carboxylic acid azide represented by a general formula:




wherein R, R¹, R², R³, R⁴, R⁵ and R⁶ indicate the same groups as the groups indicated in the general formula (VI).

(19). A process for producing a 5-fluorouracil derivative of claim 6, which comprises: reacting a 5-fluorouracil derivative represented by the following formula:



and an amine represented by a general formula:



wherein R, R¹, R², R³, R⁴, R⁵ and R⁶ indicate the same groups as the groups indicated in the general formula (VI).

(19)



Europäisches Patentamt
European Patent Office
Office européen des brevets

(11) Publication number:

0 240 352
A3

(12)

EUROPEAN PATENT APPLICATION

(21) Application number: 87302884.9

(51) Int. Cl. 4: **C07D 239/54 , C07D 401/12 ,**
C07D 403/12 , A61K 31/505

(22) Date of filing: 02.04.87

(30) Priority: 02.04.86 JP 74297/86
03.02.87 JP 21727/87

(43) Date of publication of application:
07.10.87 Bulletin 87/41

(54) Designated Contracting States:
DE FR GB

(96) Date of deferred publication of the search report:
23.11.88 Bulletin 88/47


(71) Applicant: Chisso Corporation
6-32, Nakanoshima 3-chome Kita-ku
Osaka-shi Osaka-fu(JP)

(72) Inventor: Yoshizawa, Ryo
1-5-404, Grin Haitzu 363 Nagasawa
Yokosuka-shi Kanagawa-ken(JP)
Inventor: Kawashima, Masatoshi
10-3, Otsutomo-cho Kanazawa-ku
Yokohama-shi Kanagawa-ken(JP)
Inventor: Yano, Hitoshi
12-16, Kannon-cho 1-chome Kawasaki-ku
Kawasaki-shi Kanagawa-ken(JP)


(74) Representative: Whalley, Kevin et al
MARKS & CLERK 57/60 Lincoln's Inn Fields
London WC2A 3LS(GB)

(54) 5-Fluorouracil derivatives and processes for producing thereof.

(57) 5-Fluorouracil derivatives of this invention are represented by a general formula:




(I)



wherein R indicates a non-substituted or substituted alkylene group having 0-10 carbon atoms, A indicates an atomic group of -NH- and -CO-, n is 0 or 1, and Y indicates a non-substituted or substituted alkyl group having 1-10 carbon atoms, a non-substituted or substituted aryl group, a non-substituted or substituted heteroaryl group, a pyridinium ion having a halogen as a pair ion or an isocyanate group.

These derivatives are useful as anticancer medicines and intermediates thereof and have lower toxicity than usual compounds.

These derivatives are produced by specified six methods of this invention. Representative method is a process which comprises reacting 5-fluorouracil and an isocyanate represented by a general formula:



wherein R, A, n and Y are the same as those indicated in the formula (I).

EP 0 240 352 A3



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number

EP 87 30 2884

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl.4)
X	CH-A- 630 907 (MITSUI TOATSU) * Pages 1-5 * ---	1,16	C 07 D 239/54 C 07 D 401/12
X	FR-A-2 539 412 (OZAKI) * Pages 1-4,7-16,23,24 * ---	1,2,10	C 07 D 403/12 A 61 K 31/505
X	PATENT ABSTRACTS OF JAPAN, vol. 5, no. 8 (C-39)[680], 20th January 1981; & JP-A-55 136 267 (TOKYO KINZOKU KOGYO K.K.) 23-10-1980 * Abstract * ---	1,2,10	
X	PATENT ABSTRACTS OF JAPAN, vol. 5, no. 128 (C-67)[800], 18th August 1981; & JP-A-56 63 966 (TOKYO KINZOKU KOGYO K.K.) 30-05-1981 * Abstract * ---	1,16	
X	CHEMICAL ABSTRACTS, vol. 88, 1978, page 644, no. 22966p, Columbus, Ohio, US; & JP-A-77 85 179 (MITSUI TOATSU CHEMICALS, INC.) 15-07-1977 * Abstract * -----	1,10,12	TECHNICAL FIELDS SEARCHED (Int. Cl.4) C 07 D 239/00 C 07 D 401/00 C 07 D 403/00
The present search report has been drawn up for all claims			
Place of search THE HAGUE		Date of completion of the search 09-09-1988	Examiner FRANCOIS J.C.L.
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document			

EPO FORM 1503 03.82 (P0401)